|
|
 |
|
In post-9/11 world, vaccine research gains new respect Newsday Because vaccine-making is based in large part on trial and error, and there is no universal blueprint for how to do it, the process can be tedious and expensive. Scientists have had difficulty getting funding — most drug makers considered vaccines for Third World diseases such as malaria or cholera unprofitable. The work also requires a multidisciplinary team of researchers who might spend half a career or more on a single vaccine, with no guarantee of success and a high risk of failure.
—Posted: June 10, 2003
More news headlines: This week | Last week | Search archive
|
|
|
